SG11201906509WA - Lipocalin muteins with binding affinity for lag-3 - Google Patents

Lipocalin muteins with binding affinity for lag-3

Info

Publication number
SG11201906509WA
SG11201906509WA SG11201906509WA SG11201906509WA SG11201906509WA SG 11201906509W A SG11201906509W A SG 11201906509WA SG 11201906509W A SG11201906509W A SG 11201906509WA SG 11201906509W A SG11201906509W A SG 11201906509WA SG 11201906509W A SG11201906509W A SG 11201906509WA
Authority
SG
Singapore
Prior art keywords
lipocalin muteins
international
lag
present disclosure
freising
Prior art date
Application number
SG11201906509WA
Other languages
English (en)
Inventor
Christine Rothe
Shane Olwill
Andrea Allersdorfer
Timo Eichner
Aiba Rachida Siham Bel
Marina Pavlidou
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of SG11201906509WA publication Critical patent/SG11201906509WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201906509WA 2017-01-18 2018-01-18 Lipocalin muteins with binding affinity for lag-3 SG11201906509WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151945 2017-01-18
PCT/EP2018/051139 WO2018134274A1 (fr) 2017-01-18 2018-01-18 Mutéines de lipocaline ayant une affinité de liaison pour lag-3

Publications (1)

Publication Number Publication Date
SG11201906509WA true SG11201906509WA (en) 2019-08-27

Family

ID=57860697

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906509WA SG11201906509WA (en) 2017-01-18 2018-01-18 Lipocalin muteins with binding affinity for lag-3

Country Status (12)

Country Link
US (2) US11168119B2 (fr)
EP (1) EP3571219A1 (fr)
JP (1) JP7225116B2 (fr)
KR (1) KR20190104409A (fr)
CN (1) CN110402252A (fr)
AU (1) AU2018209178B2 (fr)
BR (1) BR112019014691A2 (fr)
CA (1) CA3050194A1 (fr)
MX (1) MX2019008434A (fr)
RU (1) RU2019122482A (fr)
SG (1) SG11201906509WA (fr)
WO (1) WO2018134274A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
WO2018134274A1 (fr) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Mutéines de lipocaline ayant une affinité de liaison pour lag-3
KR20210146999A (ko) 2019-03-29 2021-12-06 피어이스 파마슈티컬즈 게엠베하 리포칼린 뮤테인의 흡입 투여
US20230227568A1 (en) 2020-06-05 2023-07-20 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
EP4320141A1 (fr) * 2021-04-08 2024-02-14 Pieris Pharmaceuticals GmbH Nouvelles mutéines de lipocaline spécifiques au facteur de croissance des tissus conjonctifs (ctgf)
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
CN113754743B (zh) * 2021-10-12 2024-02-02 成都齐碳科技有限公司 孔蛋白单体的突变体、蛋白孔及其应用
WO2023118497A1 (fr) 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Nouveaux variants d'il-18

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
ATE307597T1 (de) 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AU4505399A (en) 1999-06-02 2000-12-28 Abb Research Ltd Coating composition for high temperature protection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (fr) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
ES2439580T3 (es) 2003-02-28 2014-01-23 The Johns Hopkins University Regulación de células T
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (fr) 2004-11-26 2015-07-29 Pieris AG Composé à affinité pour l'antigène associé aux lymphocytes T cytotoxiques (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
EP1996613B1 (fr) * 2006-03-20 2014-04-30 Technische Universität München Muteines de la lipocaline lacrymale presentant une affinite avec le corecepteur cd4 des lymphocytes t
EP2245054B1 (fr) 2008-01-30 2018-11-28 Pieris Pharmaceuticals GmbH Mutéines de lipocaline de larmes ayant une affinité pour le récepteur tyrosine kinase c-met humain et procédés d'obtention de celles-ci
DK3453400T3 (da) 2011-12-13 2021-04-06 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
WO2014076321A1 (fr) 2012-11-19 2014-05-22 Pieris Ag Nouveaux polypeptides de liaison spécifique et leurs utilisations
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
LT3298030T (lt) * 2015-05-18 2023-02-27 Pieris Pharmaceuticals Gmbh Sulietas polipeptidas prieš vėžį
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
WO2018134274A1 (fr) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Mutéines de lipocaline ayant une affinité de liaison pour lag-3

Also Published As

Publication number Publication date
AU2018209178A1 (en) 2019-08-01
JP2020505948A (ja) 2020-02-27
RU2019122482A (ru) 2021-02-19
US20190345207A1 (en) 2019-11-14
CN110402252A (zh) 2019-11-01
JP7225116B2 (ja) 2023-02-20
WO2018134274A1 (fr) 2018-07-26
MX2019008434A (es) 2019-11-11
CA3050194A1 (fr) 2018-07-26
US20220098253A1 (en) 2022-03-31
KR20190104409A (ko) 2019-09-09
BR112019014691A2 (pt) 2020-04-07
US11168119B2 (en) 2021-11-09
EP3571219A1 (fr) 2019-11-27
US11773147B2 (en) 2023-10-03
AU2018209178B2 (en) 2021-07-29
RU2019122482A3 (fr) 2021-05-26

Similar Documents

Publication Publication Date Title
SG11201906509WA (en) Lipocalin muteins with binding affinity for lag-3
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807187XA (en) Binding members to pd-l1
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201809341PA (en) Mobile robot
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201907927SA (en) Binding molecules that specifically bind to tau